This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (IMAC/Herbst)

This study has been withdrawn prior to enrollment.
(No patients randomised)
Information provided by:
AstraZeneca Identifier:
First received: September 2, 2004
Last updated: January 28, 2013
Last verified: January 2013
In this Phase IIIb, randomized, double-blind, maintenance study, 300 subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) (Stage IIIB {T4-pleural effusion} and IV) who have SD or objective tumor response immediately following the completion of 4-6 cycles of front line, platinum-based, doublet chemotherapy will be randomized in a double-blind manner to receive either ZD1839 or placebo.

Condition Intervention Phase
Non-Small-Cell Lung Carcinoma Drug: ZD1839 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase IIIb Randomized, Double-Blind Study Comparing Maintenance ZD1839 (IRESSA®) or Placebo Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Enrollment: 0
Study Start Date: January 2006
Estimated Study Completion Date: November 2007
Estimated Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must sign Informed Consent
  • Females and males aged 18 years and over.
  • Confirmed stage IIIB (T4-pleural effusion) and IV NSCLC.
  • Either complete response, partial response, or stable disease following at least 4 cycles (3 in the setting of intolerable toxicity) but no more than 6 cycles of definitive front line, platinum-based, doublet chemotherapy.
  • No prior EGFR therapy
  • No newly diagnosed intracerebral metastases while receiving or after completing chemotherapy
  • At least 3 weeks (21 days) but no more than 4 weeks (28 days) since last dose of chemotherapy
  • Must be completely healed from previous major oncologic surgery
  • Life expectancy of ≥ 8 weeks.

Exclusion Criteria:

  • Known severe hypersensitivity to ZD1839 or any of the excipients of these products.
  • Any evidence of clinically active interstitial lung disease (subjects with chronic, stable, radiographic changes who are asymptomatic need not be excluded).
  • Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.
  • Any unresolved chronic toxicity greater than common toxicity criteria (CTC) grade 2 from previous anticancer therapy excluding peripheral neuropathy or alopecia.
  • Evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.
  • Pregnancy or breast feeding (women of child bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.
  • Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.
  • Signs of neurological symptoms consistent with new onset spinal cord compression or CNS metastases.
  • Treatment with any systemic anticancer therapies other than the prescribed protocol chemotherapy regimen (refer to Inclusion criterion -). Exception: Palliative radiotherapy for symptom relief of lesions present at diagnosis will be allowed; however, this radiotherapy must occur prior to completion of pre-study doublet chemotherapy.
  • Males must also be willing to practice acceptable methods of birth control while taking the drug to prevent pregnancy of a partner.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00090675

Sponsors and Collaborators
Study Director: Iressa Medical Science Director AstraZeneca
  More Information Identifier: NCT00090675     History of Changes
Other Study ID Numbers: D7913L00019
Herbst trial
Study First Received: September 2, 2004
Last Updated: January 28, 2013

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017